RE, CHIARA
 Distribuzione geografica
Continente #
AS - Asia 181
EU - Europa 156
NA - Nord America 155
SA - Sud America 36
Totale 528
Nazione #
US - Stati Uniti d'America 148
SG - Singapore 75
IT - Italia 55
CN - Cina 44
HK - Hong Kong 41
BR - Brasile 31
DE - Germania 27
SE - Svezia 26
RU - Federazione Russa 13
NL - Olanda 12
IN - India 10
GB - Regno Unito 7
CA - Canada 5
FI - Finlandia 5
KR - Corea 5
AR - Argentina 3
AT - Austria 2
BE - Belgio 2
IE - Irlanda 2
IQ - Iraq 2
RO - Romania 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CY - Cipro 1
EC - Ecuador 1
GT - Guatemala 1
JP - Giappone 1
LT - Lituania 1
MX - Messico 1
OM - Oman 1
PE - Perù 1
TR - Turchia 1
Totale 528
Città #
Ashburn 40
Hong Kong 40
Shanghai 26
Singapore 26
New York 23
Milan 22
Boardman 13
Nuremberg 7
Amsterdam 6
Falkenstein 6
Pune 6
Frankfurt am Main 5
Helsinki 5
Lawrence 5
Princeton 5
Rome 4
Turin 4
Beijing 3
Dallas 3
Hyderabad 3
London 3
Moscow 3
Pyeongtaek-si 3
Rio de Janeiro 3
Seattle 3
São Paulo 3
Toronto 3
Washington 3
Belo Horizonte 2
Brussels 2
Cancello e Arnone 2
Canoas 2
Cortona 2
Dublin 2
Guangzhou 2
Osio Sotto 2
Pisa 2
Taizhou 2
Ufa 2
Yongin-si 2
Baghdad 1
Barnaul 1
Belém 1
Blumenau 1
Boa Vista 1
Borås 1
Busto Garolfo 1
Camaquã 1
Cologno Monzese 1
Cuiabá 1
Cáceres 1
Duque de Caxias 1
Erbil 1
Ferrara 1
Florence 1
Goianápolis 1
Goiânia 1
Guatemala City 1
Gunzenhausen 1
Hanover 1
Itumbiara 1
Limeira do Oeste 1
Los Angeles 1
Manaus 1
Manchester 1
Moncton 1
Mumbai 1
Muscat 1
Nicosia 1
Nova Lima 1
Novo Hamburgo 1
Ottawa 1
Padova 1
Pero 1
Phoenix 1
Porto Alegre 1
Pouso Alegre 1
Praia Grande 1
Predosa 1
Querétaro City 1
Quilmes 1
Resistencia 1
Reston 1
Riobamba 1
San Antonio 1
San Juan Bautista 1
Santa Clara 1
Sector 3 1
Shenzhen 1
Sorocaba 1
Temecula 1
Tuzla 1
Varna 1
Vicência 1
Vienna 1
Vila Velha 1
Volta Redonda 1
Xi'an 1
Xiamen 1
Yorii 1
Totale 360
Nome #
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 45
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 44
How to Select the Optimal Candidates for Renal Mass Biopsy 40
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 39
Parenchymal biopsy in the management of patients with renal cancer 39
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 38
"Case of the month from San Raffaele Hospital, Milan, Italy: paraneoplastic presentation of small renal masses" 36
The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy 35
Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time 35
Differential Prognostic Value of Extrarenal Involvement in Patients With Non-Metastatic Renal Cell Cancer 32
Centralization of care for rare genetic syndromes associated with cancer: improving outcomes and advancing research on VHL disease 31
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 29
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 27
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 26
Influences of Age and Comorbidities on Indication for Partial Nephrectomy: A Systematic Review 22
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 21
Pulmonary lesion after surgery for renal cancer: progression or new primary? 20
Totale 559
Categoria #
all - tutte 4.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.542


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 1 0 2 0 0 0 0 0 0 0 5
2022/202352 10 9 3 5 3 6 4 6 2 0 1 3
2023/2024186 11 8 12 12 9 35 0 46 0 8 10 35
2024/2025313 28 12 22 30 24 20 55 52 56 14 0 0
Totale 559